J
John M. Timmerman
Researcher at University of California, Los Angeles
Publications - 162
Citations - 17080
John M. Timmerman is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Lymphoma & Follicular lymphoma. The author has an hindex of 40, co-authored 141 publications receiving 13138 citations. Previous affiliations of John M. Timmerman include Brigham and Women's Hospital & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu,Frederick L. Locke,Nancy L. Bartlett,Lazaros J. Lekakis,David B. Miklos,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick J. Stiff,Jonathan W. Friedberg,Ian W. Flinn,Andre Goy,Brian T. Hill,Mitchell R. Smith,Abhinav Deol,Umar Farooq,Peter A. McSweeney,Javier Munoz,Irit Avivi,Januario E. Castro,Jason R. Westin,Julio C. Chavez,Armin Ghobadi,Krishna V. Komanduri,Ronald Levy,Eric D. Jacobsen,Thomas E. Witzig,Patrick M. Reagan,Adrian Bot,John J. Rossi,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,David Z. Chang,Jeff Wiezorek,William Y. Go +39 more
TL;DR: Patients with refractory large B‐cell lymphoma who received CAR T‐cell therapy with axi‐cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events.
Journal ArticleDOI
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell,Alexander M. Lesokhin,Alexander M. Lesokhin,Ivan Borrello,Ahmad Halwani,Emma C. Scott,Martin Gutierrez,Stephen J. Schuster,Michael Millenson,Deepika Cattry,Gordon J. Freeman,Scott J. Rodig,Bjoern Chapuy,Azra H. Ligon,Lili Zhu,Joseph F. Grosso,Su Y oung Kim,John M. Timmerman,Margaret A. Shipp,Philippe Armand +19 more
TL;DR: Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma.
Journal ArticleDOI
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke,Armin Ghobadi,Caron A. Jacobson,David B. Miklos,Lazaros J. Lekakis,Olalekan O. Oluwole,Yi Lin,Ira Braunschweig,Brian T. Hill,John M. Timmerman,Abhinav Deol,Patrick M. Reagan,Patrick J. Stiff,Ian W. Flinn,Umar Farooq,Andre Goy,Peter A. McSweeney,Javier Munoz,Tanya Siddiqi,Julio C. Chavez,Alex F. Herrera,Nancy L. Bartlett,Jeffrey S. Wiezorek,Lynn Navale,Allen Xue,Yizhou Jiang,Adrian Bot,John M. Rossi,Jenny J. Kim,William Y. Go,Sattva S. Neelapu +30 more
TL;DR: Long-term activity and safety outcomes of the ZUMA-1 study suggest that axicabtagene ciloleucel can induce durable responses and a median overall survival of greater than 2 years, and has a manageable relapsed or refractory disease or relapsed after autologous stem-cell transplantation.
Journal ArticleDOI
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang,Javier Munoz,Andre Goy,Frederick L. Locke,Caron A. Jacobson,Brian T. Hill,John M. Timmerman,Houston Holmes,Samantha Jaglowski,Ian W. Flinn,Peter A. McSweeney,David B. Miklos,John M. Pagel,Marie José Kersten,Noel Milpied,Henry C. Fung,Max S. Topp,Roch Houot,Amer Beitinjaneh,Weimin Peng,Lianqing Zheng,John M. Rossi,Rajul K. Jain,Arati V. Rao,Patrick M. Reagan +24 more
TL;DR: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma, and led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies.
Journal ArticleDOI
Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study
Alexander M. Lesokhin,Alexander M. Lesokhin,Stephen M. Ansell,Philippe Armand,Emma C. Scott,Ahmad Halwani,Martin Gutierrez,Michael Millenson,Adam D. Cohen,Stephen J. Schuster,Daniel Lebovic,Madhav V. Dhodapkar,David Avigan,Bjoern Chapuy,Azra H. Ligon,Gordon J. Freeman,Scott J. Rodig,Deepika Cattry,Lili Zhu,Joseph F. Grosso,M. Brigid Bradley Garelik,Margaret A. Shipp,Ivan Borrello,John M. Timmerman +23 more
TL;DR: Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas and PD-L1/PD-L2 locus integrity and protein expression.